Venture Capital

With $70M and a new CEO, Prolynx is leveraging a cancer-tested platform to create monthly obesity shots. Can it disrupt a billion-dollar market?

With a 2026 decision date set, Lifezone Metals is de-risking a world-class nickel project in Tanzania, promising to shake up the global battery supply chain.

The U.S. Coast Guard taps AeroVironment for advanced underwater robots, a key step in its Force Design 2028 plan to boost safety and mission efficiency.

RecycLiCo's new R&D hub is more than just a building; it's a strategic play in the high-stakes game of critical mineral independence.

As AI-driven fakes flood the world, a new asset class is born: authenticity. Discover how GME and Reality Defender are monetizing trust for government.

Beyond the hype, one company's dual leadership award reveals the true engine of the GenAI revolution: a smarter, more powerful search foundation.

Bill Ackman's fund posted a stellar 24.1% return. We dive into the high-conviction plays and innovative structure driving this market-beating performance.

With FDA approval and $80M in funding, ProVerum’s ProVee system aims to disrupt the BPH treatment market by prioritizing safety and patient quality of life.

A new partnership uses AI to analyze imaging, clinical, and molecular data, offering unprecedented accuracy in predicting breast cancer recurrence years later.

Serina Therapeutics has answered the FDA's challenge. A 30-day clock now ticks on its novel Parkinson's therapy and its disruptive drug delivery platform.

Early trial data suggests GRI-0621 could be a game-changer for Idiopathic Pulmonary Fibrosis, showing lung repair and a much better safety profile.

BridgeBio Oncology's new drug candidate BBO-10203 could redefine cancer therapy by avoiding a key toxicity, unlocking a vast market.

Aardvark Therapeutics' pivotal trial for Prader-Willi syndrome goes global, a key step toward commercializing its novel hunger-suppressing drug.

The eyewear giant is moving beyond frames, partnering to design custom chips. A strategic pivot to open-source hardware aims to redefine the market.

With Sir Nick Clegg and AI pioneer Yann LeCun on board, HIRO Capital's new fund is a bold bet on Europe's ability to lead in deep tech innovation.

A V2G pioneer pivots its intelligent software to compete for a massive national energy storage contract in South Korea's booming, high-stakes market.

The 2025 proxy season saw record director support as investors prioritized financials, yet dissent over executive pay signals a new battleground.

With a new patent, this biotech targets the massive orthopedics market. But can its novel fibroblast therapy overcome steep financial and clinical hurdles?

A showcase in LA reveals Hollywood's strategy to tap Korean creative power, with new IPs like 'Oh My Ghost Clients' poised for a global breakthrough.

USA Rare Earth is accelerating its timeline to mine critical minerals by two years. Can innovative tech and bold strategy break foreign supply chain dominance?